Global Information
회사소개 | 문의 | 위시리스트

대장염 : 파이프라인 리뷰

Colitis - Pipeline Review, H1 2019

리서치사 Global Markets Direct
발행일 2019년 02월 상품 코드 232843
페이지 정보 영문 117 Pages
가격
US $ 2,000 ₩ 2,429,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,858,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,287,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


대장염 : 파이프라인 리뷰 Colitis - Pipeline Review, H1 2019
발행일 : 2019년 02월 페이지 정보 : 영문 117 Pages

대장염이란 대장의 염증을 가리키며, 바이러스, 기생충, 식중독(박테리아) 등에 의한 감염, 염증성 질환(궤양성 대장염, 크론병), 혈류 부족(허혈성 대장염), 대장에 대한 과거 피폭 등 다양한 원인이 있습니다. 복통, 고창(鼓腸), 혈변, 오한, 탈수, 설사, 발열 등의 증상이 나타나며, 비스테로이드성 항염증제(NSAID), 코르티코스테로이드 등의 치료법이 있습니다.

세계의 대장염(Colitis) 치료제 파이프라인 개발 상황에 대해 조사했으며, 현재의 개발 파이프라인 상황과 최신 동향, 치료제 개요, 주요 기업 및 개발중인 제품 리뷰 등의 정보를 전해드립니다.

목차

서론

  • 조사 범위

대장염 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

기업에서 개발중인 치료제

대학/연구기관에서 연구중인 치료제

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 연구중인 제품

치료제 개발에 참여하고 있는 기업

  • Aerpio Therapeutics, Inc.
  • Ajinomoto Pharmaceuticals Co., Ltd.
  • Akebia Therapeutics, Inc.
  • Amorepacific Corporation
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dr. Falk Pharma GmbH
  • Galapagos NV
  • Immuron Limited
  • Innate Pharma S.A.
  • Peptinov SAS
  • Pfizer Inc.
  • Prokarium Limited
  • Protalix BioTherapeutics, Inc.
  • RDD Pharma Ltd.
  • Saniona AB
  • Synovo GmbH

치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기전별
  • 투여경로별
  • 분자종류별

치료제 개요

  • AcTMP-1
  • AKB-4924
  • AKB-6899
  • AN-346
  • Antibodies to Inhibit Heparanase for Cancer
  • Antibody for Colitis
  • Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis
  • APY-0201
  • BC-1215
  • BMS-986104
  • budesonide
  • Clostridium difficile vaccine
  • CSY-0073
  • Drugs to Antagonize TRP Channel for Inflammatory Diseases and C
  • etanercept biosimilar
  • filgotinib
  • IMM-124E
  • IPH-33
  • mesalamine
  • NK-007
  • PAC-14028
  • Peptide to Inhibit NFkB for Colitis and Enteritis
  • PF-06425090
  • PPV-06
  • RDD-2007
  • Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis
  • Small Molecule for Colitis
  • Synthetic Peptides to Inhibit Panx1 for Colitis
  • Vaccine to Target Interleukin 12 and Interleukin 23 for Colitis
  • Vaccine to Target Interleukin-23 for Colitis
  • ZK-216348

최근의 파이프라인 동향

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주요 뉴스와 프레스 릴리스

부록

도표

LSH 16.04.04

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Colitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Colitis - Pipeline by AlfaSigma SpA, H1 2019
  • Colitis - Pipeline by Apollo Endosurgery Inc, H1 2019
  • Colitis - Pipeline by Concenter BioPharma Silkim Ltd, H1 2019
  • Colitis - Pipeline by Dr. Falk Pharma GmbH, H1 2019
  • Colitis - Pipeline by enGene Inc, H1 2019
  • Colitis - Pipeline by Genfit SA, H1 2019
  • Colitis - Pipeline by Handa Pharmaceuticals LLC, H1 2019
  • Colitis - Pipeline by Immodulon Therapeutics Ltd, H1 2019
  • Colitis - Pipeline by Immuron Ltd, H1 2019
  • Colitis - Pipeline by Inflazome Ltd, H1 2019
  • Colitis - Pipeline by Nippon Kayaku Co Ltd, H1 2019
  • Colitis - Pipeline by Ogeda SA, H1 2019
  • Colitis - Pipeline by Principia Biopharma Inc, H1 2019
  • Colitis - Pipeline by Protagonist Therapeutics Inc, H1 2019
  • Colitis - Pipeline by RDD Pharma Ltd, H1 2019
  • Colitis - Pipeline by Saniona AB, H1 2019
  • Colitis - Pipeline by Scholar Rock Inc, H1 2019
  • Colitis - Pipeline by Soligenix Inc, H1 2019
  • Colitis - Pipeline by Synthetic Biologics Inc, H1 2019
  • Colitis - Pipeline by Vitality Biopharma Inc, H1 2019
  • Colitis - Dormant Projects, H1 2019
  • Colitis - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Colitis - Dormant Projects, H1 2019 (Contd..2), H1 2019
  • Colitis - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Colitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Top 10 Targets, H1 2019
  • Number of Products by Stage and Top 10 Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colitis - Pipeline Review, H1 2019, provides an overview of the Colitis (Gastrointestinal) pipeline landscape.

Colitis is swelling (inflammation) of the large intestine (colon). Colitis can have many different causes, including infections, including those caused by a virus, parasite, and food poisoning due to bacteria, inflammatory disorders (ulcerative colitis and Crohn's disease), lack of blood flow (ischemic colitis), past radiation to the large bowel). Symptoms can include abdominal pain, bloating, bloody stools, chills, dehydration, diarrhea and fever. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical, Discovery and Unknown stages are 2, 3, 24, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 7 molecules, respectively.

Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Colitis (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Colitis (Gastrointestinal)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Colitis (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Colitis - Overview
  • Colitis - Therapeutics Development
  • Colitis - Therapeutics Assessment
  • Colitis - Companies Involved in Therapeutics Development
  • Colitis - Drug Profiles
  • Colitis - Dormant Projects
  • Colitis - Discontinued Products
  • Colitis - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q